RecruitingNot ApplicableNCT05324332

68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients

A Pilot Comparison of 68Ga-P16-093 and 68Ga-PSMA-11 in the Same Group of Primary Prostate Cancer Patients

Sponsor

Peking Union Medical College Hospital

Enrollment

50 participants

Start Date

Apr 15, 2022

Study Type

INTERVENTIONAL

Conditions

Prostate Cancer

Summary

Prostate-specific membrane antigen (PSMA)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect primary prostate tumor and its metastases, like the most widely studied 68Ga-PSMA-11. This pilot study was evaluate the diagnostic performance of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with 68Ga-PSMA-11 in the same group of primary prostate cancer patients.

Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study compares two PET/CT scan tracers — 68Ga-P16-093 and 68Ga-PSMA-11 — in prostate cancer patients to see which better detects cancer spread, particularly to lymph nodes and bones. **You may be eligible if...** - You have prostate cancer - You are scheduled for a PSMA PET/CT scan as part of your care - You are 18 or older - You are able to undergo both imaging procedures **You may NOT be eligible if...** - You have severe kidney disease that affects tracer clearance - You have had prior pelvic radiation affecting scan interpretation - You are unable to lie still for imaging Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG68Ga-P16-093

Intravenous injection of 68Ga-P16-093 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.

DRUG68Ga-PSMA-11

Intravenous injection of 68Ga-PSMA-11 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-PSMA-11 will be used to image lesions of prostate cancer by PET/CT.

Locations(1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05324332

Related Trials

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

NCT0700515433 locations

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

NCT0733644618 locations

Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer

NCT046926751 location

Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System

NCT068073593 locations

DESTINY-PANTUMOUR04

NCT0712400017 locations